Filing Details

Accession Number:
0001968202-24-000028
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-01-04 16:11:18
Reporting Period:
2024-01-02
Accepted Time:
2024-01-04 16:11:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc. REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1681643 Y Huda Zoghbi 777 Old Saw Mill River Road
Tarrytown NY 10591
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-01-02 1,117 $391.92 2,364 No 4 M Direct
Common Stock Disposition 2024-01-02 1,117 $900.00 1,247 No 4 S Direct
Common Stock Acquisiton 2024-01-02 135 $0.00 1,382 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2024-01-02 1,117 $0.00 1,117 $391.92
Common Stock Non-Qualified Stock Option (right to buy) Acquisiton 2024-01-02 1,607 $0.00 1,607 $888.34
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2026-09-09 No 4 M Direct
1,607 2034-01-02 No 4 A Direct
Footnotes
  1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on May 5, 2023.
  2. Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
  3. The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
  4. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.